Observational studyBreast cancer research and treatment2024

Clinical benefit of post-trastuzumab deruxtecan treatment in patients with HER 2-positive unresectable or metastatic breast cancer: A single-institution retrospective observational study.

Ayaka Isogai et al.PubMed ↗Publisher ↗

No numbers read from the abstract.